Retracted: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2020 Apr 22

PMID 32315619

Citations 45

Authors

Ken Morita

Shuning He

Radoslaw P Nowak

Jinhua Wang

Mark W Zimmerman

Cong Fu

Adam D Durbin

Megan W Martel

Nicole Prutsch

Nathanael S Gray

Eric S Fischer

A Thomas Look

Affiliations

Soon will be listed here.

Abstract

Protein phosphatase 2A (PP2A) enzymes can suppress tumors, but they are often inactivated in human cancers overexpressing inhibitory proteins. Here, we identify a class of small-molecule iHAPs (improved heterocyclic activators of PP2A) that kill leukemia cells by allosterically assembling a specific heterotrimeric PP2A holoenzyme consisting of PPP2R1A (scaffold), PPP2R5E (B56ε, regulatory), and PPP2CA (catalytic) subunits. One compound, iHAP1, activates this complex but does not inhibit dopamine receptor D2, a mediator of neurologic toxicity induced by perphenazine and related neuroleptics. The PP2A complex activated by iHAP1 dephosphorylates the MYBL2 transcription factor on Ser241, causing irreversible arrest of leukemia and other cancer cells in prometaphase. In contrast, SMAPs, a separate class of compounds, activate PP2A holoenzymes containing a different regulatory subunit, do not dephosphorylate MYBL2, and arrest tumor cells in G1 phase. Our findings demonstrate that small molecules can serve as allosteric switches to activate distinct PP2A complexes with unique substrates.

Citing Articles

gp78-regulated KAP1 phosphorylation induces radioresistance in breast cancer by facilitating PPP1CC/PPP2CA ubiquitination.

Han Y, Xiao M, Zhao S, Wang H, Li R, Xu B iScience. 2024; 27(9):110847.

PMID: 39297166 PMC: 11409047. DOI: 10.1016/j.isci.2024.110847.

Large-scale genome-wide association studies reveal the genetic causal etiology between air pollutants and autoimmune diseases.

Wen J, Zhang J, Zhang H, Zhang N, Lei R, Deng Y J Transl Med. 2024; 22(1):392.

PMID: 38685026 PMC: 11057084. DOI: 10.1186/s12967-024-04928-y.

Multimodal fused deep learning for drug property prediction: Integrating chemical language and molecular graph.

Lu X, Xie L, Xu L, Mao R, Xu X, Chang S Comput Struct Biotechnol J. 2024; 23:1666-1679.

PMID: 38680871 PMC: 11046066. DOI: 10.1016/j.csbj.2024.04.030.

The oncogene MYBL2 promotes the malignant phenotype and suppresses apoptosis through hedgehog signaling pathway in clear cell renal cell carcinoma.

Yang W, Chen H, Ma L, Wei M, Xue X, Li Y Heliyon. 2024; 10(6):e27772.

PMID: 38510035 PMC: 10950673. DOI: 10.1016/j.heliyon.2024.e27772.

Altering phosphorylation in cancer through PP2A modifiers.

Johnson H, Narayan S, Sharma A Cancer Cell Int. 2024; 24(1):11.

PMID: 38184584 PMC: 10770906. DOI: 10.1186/s12935-023-03193-1.

References

Hwang J, Lee J, Pallas D . Leucine Carboxyl Methyltransferase 1 (LCMT-1) Methylates Protein Phosphatase 4 (PP4) and Protein Phosphatase 6 (PP6) and Differentially Regulates the Stable Formation of Different PP4 Holoenzymes. J Biol Chem. 2016; 291(40):21008-21019. PMC: 5076511. DOI: 10.1074/jbc.M116.739920. View

Hertz E, Kruse T, Davey N, Lopez-Mendez B, Sigurdsson J, Montoya G . A Conserved Motif Provides Binding Specificity to the PP2A-B56 Phosphatase. Mol Cell. 2016; 63(4):686-695. DOI: 10.1016/j.molcel.2016.06.024. View

Hals P, Hall H, Dahl S . Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol. 1986; 125(3):373-81. DOI: 10.1016/0014-2999(86)90793-4. View

Morita K, Masamoto Y, Kataoka K, Koya J, Kagoya Y, Yashiroda H . BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia. 2015; 29(11):2248-56. DOI: 10.1038/leu.2015.137. View

Li Z, He S, Look A . The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 2018; 33(1):262-266. PMC: 6327051. DOI: 10.1038/s41375-018-0201-2. View

Miller R . Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Curr Neuropharmacol. 2010; 7(4):315-30. PMC: 2811865. DOI: 10.2174/157015909790031184. View

Gutierrez A, Pan L, Groen R, Baleydier F, Kentsis A, Marineau J . Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest. 2014; 124(2):644-55. PMC: 3904599. DOI: 10.1172/JCI65093. View

Lynch 3rd J, Castagne V, Moser P, Mittelstadt S . Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Methods. 2011; 64(1):74-80. DOI: 10.1016/j.vascn.2011.03.003. View

Cahill H, Rattner A, Nathans J . Preclinical assessment of CNS drug action using eye movements in mice. J Clin Invest. 2011; 121(9):3528-41. PMC: 3163951. DOI: 10.1172/JCI45557. View

10.

Horstmann S, Ferrari S, Klempnauer K . An alternatively spliced isoform of B-Myb is a transcriptional inhibitor. Oncogene. 2000; 19(48):5428-34. DOI: 10.1038/sj.onc.1203937. View

11.

Cundell M, Hutter L, Bastos R, Poser E, Holder J, Mohammed S . A PP2A-B55 recognition signal controls substrate dephosphorylation kinetics during mitotic exit. J Cell Biol. 2016; 214(5):539-54. PMC: 5004449. DOI: 10.1083/jcb.201606033. View

12.

Werwein E, Cibis H, Hess D, Klempnauer K . Activation of the oncogenic transcription factor B-Myb via multisite phosphorylation and prolyl cis/trans isomerization. Nucleic Acids Res. 2018; 47(1):103-121. PMC: 6326806. DOI: 10.1093/nar/gky935. View

13.

Seeman P . Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010; 4(1):56-73. DOI: 10.3371/CSRP.4.1.5. View

14.

Crawley J . Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 1999; 835(1):18-26. DOI: 10.1016/s0006-8993(98)01258-x. View

15.

McKinley K, Cheeseman I . Large-Scale Analysis of CRISPR/Cas9 Cell-Cycle Knockouts Reveals the Diversity of p53-Dependent Responses to Cell-Cycle Defects. Dev Cell. 2017; 40(4):405-420.e2. PMC: 5345124. DOI: 10.1016/j.devcel.2017.01.012. View

16.

Prinz H, Ridder A, Vogel K, Bohm K, Ivanov I, Ghasemi J . N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization. J Med Chem. 2017; 60(2):749-766. DOI: 10.1021/acs.jmedchem.6b01591. View

17.

Sadasivam S, DeCaprio J . The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013; 13(8):585-95. PMC: 3986830. DOI: 10.1038/nrc3556. View

18.

Ruvolo P . The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016; 6:87-99. PMC: 4986044. DOI: 10.1016/j.bbacli.2016.08.002. View

19.

McClinch K, Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A . Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78(8):2065-2080. PMC: 5899650. DOI: 10.1158/0008-5472.CAN-17-0123. View

20.

Sontag J, Nunbhakdi-Craig V, Sontag E . Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells. J Biol Chem. 2013; 288(38):27396-27405. PMC: 3779734. DOI: 10.1074/jbc.M113.490102. View